Prakash Bang v. Glaxo Smithkline Pharma. Ltd.
In short. The case involves an appeal by Prakash Bang against Glaxo Smithkline Pharmaceuticals Ltd. regarding a complaint of adverse effects from the vaccine Engerix-B. The National Consumer Disputes Redressal Commission (NCDRC) dismissed Bang's complaint, stating he failed to prove any defect in the drug or negligence by the manufacturer. The Supreme Court upheld the NCDRC's decision, emphasizing the lack of evidence linking the vaccine to the appellant's medical condition.
Facts
Prakash Bang sought vaccination against Hepatitis B for himself and his family on August 10, 1998, receiving the Engerix-B vaccine. While his family experienced no adverse reactions, Bang developed severe shoulder pain four days post-vaccination. Despite consultations with various medical professionals and tests, no definitive cause was identified. Bang later attributed his condition to 'myositis' as an adverse reaction to the vaccine and sought compensation of Rs. 90,20,557 from the NCDRC, which was dismissed for lack of evidence.
Arguments
Petitioner Arguments
Bang argued that the vaccine caused him permanent disability due to an adverse reaction, claiming negligence on the part of the manufacturer. He contended that the NCDRC failed to consider the medical evidence supporting his claim. The court, however, found that Bang did not provide sufficient evidence to establish a direct link between the vaccine and his condition, nor did he demonstrate any negligence by the manufacturer.
Respondent Arguments
The respondents, Glaxo Smithkline, contended that the vaccine was safe and that Bang's medical issues were unrelated to the vaccine. They argued that the appellant had not substantiated his claims with credible medical evidence. The court agreed, noting that the absence of a causal relationship between the vaccine and Bang's condition was pivotal in dismissing the complaint.
Precedents considered
The judgment did not cite specific precedents but relied on established legal principles regarding consumer protection and the burden of proof in negligence claims. The court emphasized that the complainant must demonstrate a clear link between the product and the alleged harm.
Legal principles
The court considered the legal standards surrounding consumer protection, particularly the necessity for the complainant to prove a defect in the product or negligence by the manufacturer. The principles of causation and the burden of proof were central to the court's analysis.
Decision and reasoning
Rationale
The court reasoned that Bang's failure to provide conclusive medical evidence linking the vaccine to his condition was critical. The judgment highlighted the importance of substantiating claims with credible evidence, particularly in cases involving medical products. The court also noted that the appellant's medical history did not convincingly support his claims of negligence or defect.
Outcome
The Supreme Court upheld the NCDRC's dismissal of Bang's complaint, affirming that he had not established a case for compensation. The court did not provide specific instructions for an appeal process, as the decision was final.
Conclusion
This judgment underscores the rigorous standards of proof required in consumer protection cases, particularly those involving medical products. It highlights the necessity for claimants to provide clear and convincing evidence of causation and negligence to succeed in such claims.
Read the full judgment on the Supreme Court website (PDF)
Find the judgments that followed or distinguished it, with the paragraph relied on in each. Two answers free on WhatsApp, no signup.